Ergomed logo

ERGO - Ergomed News Story

685p -5.0  -0.7%

Last Trade - 10:20am

Small Cap
Market Cap £334.0m
Enterprise Value £325.2m
Revenue £68.3m
Position in Universe 625th / 1807

Ergomed plc - Board Changes

Tue 2nd October, 2018 2:47pm
RNS Number : 7317C
Ergomed plc
02 October 2018






Board Changes


Michael Spiteri appointed Non-Executive Director to help drive digitization strategy


London, UK - 2 October 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces two Board changes with immediate effect.


Michael Spiteri joins the Board as Non-Executive Director. Michael has nearly 30 years' experience working in information technology and digital transformation. At Santander's UK Corporate and Commercial Banking business, he is responsible for digital strategy, process transformation and digital implementation across all areas of the business including automation and machine learning. Prior to Santander, Michael held partner roles at Elixirr Partners LLP and PricewaterhouseCoopers LLP and senior executive roles at Accenture and IBM as well as senior management roles at HCL Axon and Oracle with a focus on financial services clients. Michael received a BSc in Mechanical Engineering from Paisley College of Technology.


Andrew Mackie is stepping down as Chief Business Officer and Board member following the Company's announcement in April to shift its strategy to focus on services.


Peter George, Chairman of Ergomed, said: "The use of digital technology to drive both efficiency and accuracy is a strategic priority for Ergomed, particularly in our pharmacovigilance business. As a leader in the world of digitization, automation and AI, Michael's experience and counsel will be invaluable to our Board as we optimise the Group's operations and drive growth. I look forward to his input and welcome him to the team.


"I would also like to recognize Andrew's contribution to Ergomed over the last three years as an executive and for several years before that as a consultant. We wish him well in his future endeavours."


Michael Spiteri, Non-Executive Director of Ergomed, said: "Ergomed is at a key juncture as it embraces and takes advantage of the opportunities presented by automation and AI. I'm delighted to be joining the Ergomed Board and I am looking forward to contributing to the roll-out of its digitization strategy".


Additional Information


Michael William Spiteri (57) has held the following directorships/partnerships in the past five years:



Behavioural Innovation Ltd: Director



PriceWaterHouseCoopers LLP: LLP Member

Elixirr Partners LLP: LLP Member


Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Michael Spiteri's appointment.


- Ends -




Ergomed plc

   Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.